This talk discusses a CRISPR-Cas9 based platform for in vivo screening of immune genes. This platform facilitates discovery of regulators of tumor immunity and targets for combination therapy. We will discuss the use of this platform to perform in vivo CRISPR-based screens to enable rapid discovery of therapeutic targets in immune cells, and our identification of Ptpn2 as a negative regulator of exhausted CD8+ T cell responses using this CRISPR platform.
Citation Format: Arlene H. Sharpe. Discovery of new immunotherapy targets and mechanisms leveraging CRISPR [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr IA16.